幽门螺杆菌阴性胃黏膜相关淋巴组织淋巴瘤的研究进展  

Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma

作　　者：安亚楠 王端然 郭甜甜 武希润[1] An Yanan;Wang Duanran;Guo Tiantian;Wu Xirun(Second Clinical Medical School,Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第二临床医学院,太原030001

出　　处：《中华消化病与影像杂志（电子版）》2024年第3期268-274,共7页Chinese Journal of Digestion and Medical Imageology(Electronic Edition)

摘　　要：随着医疗技术的发展,越来越多的证据表明,胃黏膜相关淋巴组织(MALT)淋巴瘤的发生与幽门螺杆菌(Hp)的感染密切相关。通过单纯根除Hp治疗已成为该疾病的一线治疗方案。但目前发现,还有绝大部分胃MALT淋巴瘤患者不存在Hp感染,Hp阴性的胃MALT淋巴瘤的发病机制、内镜临床表现和治疗方式与阳性患者存在不同。且治疗方案存在争议。本文总结了Hp为阴性的胃MALT淋巴瘤的发病机制、临床表现及治疗方案,并对未来治疗进行展望,为提高该疾病的治愈率以及降低不良反应发生率提供参考。With the development of medical technology,more and more evidence shows that the occurrence of gastric mucosa-associated lymphoid tissue(MALT)lymphoma is closely related to the infection of Helicobacter pylori(Hp).Treatment by simple eradication of Hp has become the first-line treatment for the disease.However,it has been found that most patients with gastric MALT lymphoma do not have Hp infection,and the pathogenesis,endoscopic clinical manifestations and treatment methods of HP-negative gastric MALT lymphoma are different from those of positive patients.And treatment options are controversial.In this paper,the pathogenesis,clinical manifestations and treatment of HP-negative gastric MALT lymphoma are summarized,and the future treatment is prospected,so as to provide reference for improving the cure rate of this disease and reducing the incidence of adverse reactions.

关 键 词：胃黏膜相关淋巴组织淋巴瘤 螺杆菌 幽门 发病机制 诊断与治疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]